NCT02030639View on ClinicalTrials.gov

Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

August 31, 2015

Conditions
Healthy
Interventions
DRUG

rigosertib

A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib (\[14C\]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.

Trial Locations (1)

53704

Covance Clinical Research Unit, Inc., Madison

All Listed Sponsors
lead

Traws Pharma, Inc.

INDUSTRY

NCT02030639 - Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers | Biotech Hunter | Biotech Hunter